Editorial| Volume 43, ISSUE 5, P853-855, May 2017

An outlook on precision surgery

Published:December 13, 2016DOI:
      The concept of precision surgery involves much more than a mastery of technical maneuvers. The definition of such precision is more sophisticated and involves a deeper understanding of the underlying biological foundation of disease that is then challenged with targeted, strategic interventions. Rather than treating many to benefit a few, precision surgery aims to apply surgical therapy to those most likely to benefit and to avoid surgery in those doomed to fail. In the realm of surgical oncology, the concept of precision may be decades old. Dr. Blake Cady, in his 1996 Presidential Address to the New England Surgical Society, summarized this concept well by stating that ‘the art of surgical oncology is to apply basic principles flexibly to the individual patient.’
      • Cady B.
      Basic principles in surgical oncology.
      Herein, previous efforts exemplifying precision medicine will be reviewed, followed by a series of advancements that are demonstrative of the promise of precision in surgical oncology.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cady B.
        Basic principles in surgical oncology.
        Arch Surg. 1997; 132: 338-346
        • Slamon D.J.
        • Leyland-Jones B.
        • Shak S.
        • et al.
        Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
        N Engl J Med. 2001; 344: 783-792
        • Paik S.
        • Shak S.
        • Tang G.
        • et al.
        A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
        N Engl J Med. 2004; 351: 2817-2826
        • Sobrero A.F.
        • Maurel J.
        • Fehrenbacher L.
        • et al.
        EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
        J Clin Oncol. 2008; 26: 2311-2319
        • Cunningham D.
        • Humblet Y.
        • Siena S.
        • et al.
        Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
        N Engl J Med. 2004; 351: 337-345
        • Bokemeyer C.
        • Van Cutsem E.
        • Rougier P.
        • et al.
        Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.
        Eur J Cancer. 2012; 48: 1466-1475
        • Alexander E.K.
        • Kennedy G.C.
        • Baloch Z.W.
        • et al.
        Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.
        N Engl J Med. 2012; 367: 705-715
        • Hawkins W.G.
        • DeMatteo R.P.
        • Jarnagin W.R.
        • Ben-Porat L.
        • Blumgart L.H.
        • Fong Y.
        Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer.
        Ann Surg Oncol. 2004; 11: 310-315
        • Balachandran V.P.
        • Arora A.
        • Gonen M.
        • et al.
        A validated prognostic multigene expression assay for overall survival in resected colorectal cancer liver metastases.
        Clin Cancer Res. 2016; 22: 2575-2582
        • Passiglia F.
        • Bronte G.
        • Bazan V.
        • Galvano A.
        • Vincenzi B.
        • Russo A.
        Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
        Crit Rev Oncol Hematol. 2016; 99: 150-157